Aldurazyme® (laronidase) logo

Aldurazyme® (laronidase) Copay Program


Jump to:

  

Helping eligible patients with out-of-pocket costs.

CareConnect Personalized Support Services Copay Assistance Programa helps eligible patients in the United States who are prescribed Aldurazyme pay for their qualifying out-of-pocket drug costs and certain infusion‑related expenses (mixing and administration of the drug, as well as infusion supplies such as, for example, saline and IV tubing), including copays, coinsurance, and deductibles.

The programa is open to individuals who:

  • Have commercial insurance
  • Have prescription drug coverage
  • Are prescribed one of Sanofi’s treatments
  • Are residents of the United States

   
Not valid for
 prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs including any state pharmaceutical assistance programs. No claim for reimbursement of any out-of-pocket costs covered by the Copay Program may be submitted to any third-party payer, whether public or private, including but not limited to patients’ insurance, Flexible Spending Account (FSA), Health Savings Account (HSA), or any other type of medical savings account.

This program is not valid where prohibited by law, taxed, or restricted. Sanofi reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Any savings provided by the program may vary depending on patients’ out-of-pocket costs. Patients will receive all program details upon registration.
   

CareConnect personalized support services logo

Applying for the CareConnect Copay Program

Patients or their caregivers interested in applying for the CareConnect Copay Program will need to complete the following application.

Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs including any state pharmaceutical assistance programs. No claim for reimbursement of any out-of-pocket costs covered by the Copay Program may be submitted to any third-party payer, whether public or private, including but not limited to patients’ insurance, Flexible Spending Account (FSA), Health Savings Account (HSA), or any other type of medical savings account. This program is not valid where prohibited by law, taxed, or restricted. Sanofi reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Any savings provided by the program may vary depending on patients’ out-of-pocket costs. Patients will receive all program details upon registration.

Patient Assistance Program

If your patient does not have insurance, or their insurance has denied coverage for Aldurazyme, they may be eligible to receive Aldurazyme through the Patient Assistance Program (PAP), where free product is provided through Sanofi Cares North America. To see if your patient qualifies, you will need to initiate a CareConnect PAP application. This can be done on paper or online, call the team at 1-800-745-4447, opt. 3, to learn how.

CareConnect Personalized Support Services is a trademark of Sanofi or an affiliate.

Icon representing the copay assistance program information

Coverage, coding, and reimbursement for Aldurazyme

Indication

ALDURAZYME® (laronidase) is indicated for the treatment of adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms.

Limitations of Use:

  • The safety and effectiveness of treating mildly affected patients with the Scheie form have not been established.
  • The effect of ALDURAZYME on central nervous system manifestations of the disorder has not been determined.

Important Safety Information

WARNING: HYPERSENTIVITIY REACTIONS INCLUDING ANAPHYLAXIS, and ACUTE RESPIRATORY COMPLICATIONS ASSOCIATED WITH ADMINISTRATION

Hypersensitivity Reactions Including Anaphylaxis
Patients treated with ALDURAZYME  have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available during ALDURAZYME administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue ALDURAZYME immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reactions, a desensitization procedure to ALDURAZYME may be considered.

Acute Respiratory Complications Associated with Administration
Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to infusion reactions and require additional monitoring.

Warnings and Precautions
Hypersensitivity Reactions Including Anaphylaxis: See Boxed WARNING.

  • Pre-existing upper airway obstruction may contribute to the severity of some reactions. Consider premedicating patients with antihistamines, with or without antipyretics. Because of the potential for recurrent reactions, some patients who experience initial severe reactions may require prolonged observation.
  • Consider risks and benefits of re-administering ALDURAZYME following severe hypersensitivity reactions. Patients may be rechallenged using slower infusion rates which may be increased if tolerated to reach the recommended rate. If a mild or moderate hypersensitivity reaction occurs, consider temporarily holding the infusion or slowing the infusion rate.

Acute Respiratory Complications Associated with Administration: See Boxed WARNING.

  • Patients with an acute febrile or respiratory illness may be at greater risk for infusion reactions. Consider the patient’s clinical status prior to administration of ALDURAZYME and consider delaying the infusion.
  • Evaluation of airway patency should be considered prior to initiating ALDURAZYME. Patients using supplemental oxygen or continuous positive airway pressure (CPAP) during sleep should have these treatments readily available during infusion in the event of an infusion reaction or extreme drowsiness/sleep induced by antihistamine use.

Acute Cardiorespiratory Failure:

  • Use caution when administering ALDURAZYME to patients susceptible to fluid overload, or with an acute underlying respiratory illness or compromised cardiac and/or respiratory function for whom fluid restriction is indicated. Consider a decreased total infusion volume and infusion rate when administering ALDURAZYME to these patients.

Infusion-Associated Reactions:

  • ALDURAZYME may cause infusion-associated reactions (IARs). Consider pre-medicating with antihistamines, with or without antipyretics, however IARs may still occur in patients after receiving pre-medication. Discontinue immediately or adjust the infusion rate based on the severity of the reaction.

Adverse Reactions
Patients 6 months of age and older

  • The most common adverse reactions reported in ≥10% of patients were infusion reactions, which included pyrexia, chills, blood pressure increased, tachycardia, and oxygen saturation decreased.

Patients 6 years of age and older

  • The most common adverse reactions reported in ≥10% of patients were rash, upper respiratory tract infection, injection site reaction, hyperreflexia, paresthesia, flushing, and poor venous access.

Please see Full Prescribing Information including Boxed WARNING for Aldurazyme.

Indication

Important Safety Information

© 2025 Sanofi. All rights reserved. All trademarks are owned by Sanofi or an affiliate. Aldurazyme is a registered trademark of BioMarin/Genzyme LLC. MAT-US-2205139-v2.0-08/2025